Thank you and good afternoon on my behalf as well. And welcome to listen to Orion.
Q1 2026 results. Some highlights from this Q1: all our businesses performed solidly and very well, I would say so.
And we also have good news regarding our clinical pipeline. We have been granted orphan drug designation for ODM 212 in mesothelioma by FDA in April. And we also started a new Phase 1b/2 study called TEADCO, which is a basket trial evaluating ODM-212 in combination with standard of care treatments in patients with selected advanced solid tumors. And I will talk more about that later on.
Also, we have strengthened our executive team by appointing Mr. Berkeley Vincent has been appointed as an Executive Vice President to lead Innovative Medicines Division and as a member of my executive team. As of April 8th.
So let's look at the financials.
Net sales saw a healthy growth of almost 18% compared to the previous year's Q1. Also, operating profit grew by 47%, which brought us to an operating profit margin of 27.5%, and earnings per share increased by 7%. Looking at net sales in more detail.
Innovative Medicines drove the net sales growth with royalties and tablet sales. But as mentioned. As I already mentioned, all the divisions are performing well. Of course, in relation to the size of the division. So, Branded Products growth was 5.2 million, Generics 1.9 million, and Animal Health 1.1 million.
And even Fermion external sales grew 1.8 million, totaling €480 million of net sales during Q1.
And the operating profit consists, of course, of the royalties here in column three, close to €41 million, and a change in sales volume of €21 million. We of course, see some effect on decreasing prices as we usually see, the biggest products suffering from this are, of course, Simdax and Dexdomitor, but there are other generics as well. This comprises €9.3 million.
That also includes effects and changes in cost of goods.
No major milestones received in Q1.
And then we also see an increase in our fixed costs.
And thus our operating profit was close to €150 million during Q1.
Now to Innovative Medicines, the division growth was close to 54%. And here we can see the Nubeqa royalties and tablet sales. The total is 145. Close to €145 million. Some other business of €5.4 million, which is usually sales of services to our partners. Sales of services to our partners, resulting in €150 million of net sales.
And as we remember from the previous years, we start with the lower royalty rate from Bayer in the beginning of the year. So the royalties are tiered during the financial year. And we see in Q1 clearly a lower Nubeqa income compared to the last quarter of the previous year, but clearly a higher Nubeqa revenue compared to the prior year's Q1, with royalties at €95 million and tablet sales to Bayer at €50 million.
Branded Products saw close to 7% growth compared to the previous year, with €82.2 million. Easyhaler continues to drive growth in this division, especially budesonide Formoterol, as the recent changes in treatment guidelines from last year favor the use of combination products over the mono products, and we've been able to really increase our sales according to this new guideline. And the good growth momentum in women's health therapy area continues with the HRT products.
Generics and Consumer Health 1.4% growth.
It's according to market growth, maybe slightly below that. But this is only one quarter. And we all know that this is really a very wide portfolio in many different geographies.
So this is a very good achievement for the first quarter, and Animal Health 3.3% growth.
Of course, again, a very wide portfolio both for companion animals and livestock and a global portfolio. And the growth comes from all of the different geographies and both segments or both units. When we look at the top ten products, of course, we see the Nubeqa as we discussed driving the growth. Easyhaler 7% growth. Entacapone was slightly down compared to the previous year's first quarter. But this is mainly again, a timing issue of deliveries to different regions and different partners.
Same goes with the Dexdomitor and the Animal Health DDA portfolio number four here, which grows almost 11%. And that is again a result of delayed deliveries leaving during Q1. And as I mentioned, women's health continues good growth trajectory with almost 15% growth and Burana slightly decreasing almost 6%. That's also more of a timing issue and depends on the season.
But then we see three of our generics, Trexan, Quetiapine and Fareston, which have a very, very healthy growth.
This is partly due to the previously mentioned timing of deliveries to our partners, but also showing that, for example, Trexan is a gold standard treatment globally, used both in cancer and autoimmune diseases, and also has a solid position in our top ten products. As I already mentioned, Simdax is facing heavy generic competition in Europe. Now, Innovative Medicines during Q1 comprised 36% of our net sales, Generics 32%, and Branded Products 20%. Animal Health and Fermion together were 11% to 12% of our net sales.
Our clinical development pipeline has now expanded. The list is now a bit longer with the new combination study for ODM 212, but I'll go through the list to remind us what we have now going on. So the two first ones are studies on Nubeqa, the DASL-HiCaP for the neoadjuvant use of darolutamide in prostate cancer. ARASTEP for the biochemically recurring prostate cancer. Omaha three and four are studies for metastatic castration-resistant prostate cancer with opevesostat, a molecule that Orion has developed and then outlicensed to MSD.
Then, a somewhat odd product on this list, which otherwise features oncology products or molecules, is levosimendan. It's an old classic from Orion's portfolio, the same molecule as we have in Simdax.
And that's developed for pulmonary hypertension. And there are two Phase 3 studies ongoing with that by our partner Tenox.
Then there are phase two studies again with Opevesostat for women's cancers like breast, endometrial, and ovarian cancer. These are by MSD. And this is, of course, to test whether this mechanism of action would also work for hormonal cancers in women. CYPIDES is still ongoing. That was the phase two study that was used when the phase three studies with Opevesostat started. So the results of that study were used for planning of those phase three studies.
Those phase three TEADES is a monotherapy study, a phase two study for ODM 212 for malignant pleural mesothelioma and also for epithelioid hemangioma.
Endothelioma. These are two very rare cancers, solid tumours, and we think that this molecule, based on its mechanism of action, should have a direct anti-tumor activity to these cancer types. And the newest addition, TEADCO, refers to combinations. The indications here the cancers are mesothelioma, non-small cell lung cancer, and pancreatic cancer. Here we are combining ODM 212 with some known drugs that are used for these specific cancers. And we use another mechanism of inhibition to combat or prevent the drug resistance that patients usually show to these currently used treatments. Here are some key figures from Orion's sustainability programs. Some key figures of Orion sustainability programs. We've been able to decrease our greenhouse gas emissions by 13%. And this is scope one and two. So it doesn't include Scope 3.
Our injury rate is 4.9.
And there is clearly room for improvement this year. We have very ambitious targets for LTIF. And then two things regarding the Code of Conduct, or how we operate within our own company and with our suppliers.
This has to do with the Code of Conduct in Orion. 98% of our employees have completed the training for our Code of Conduct.
Also, we conduct this Code of Conduct training and agreement with our suppliers, and 96% of our suppliers also adhere to it. Code of conduct. Our third-party Code of Conduct practices.
We have specified our outlook for this year. We gave our outlook in January, and now after Q1, when a fourth of the year has already passed, we are a bit wiser and are able to increase the lower limit of our range by 50 million, both on net sales and operating profit. So, the net sales range was 1.9 billion to €2.1 billion. In the original outlook, and now it's from €1.95 billion to €2.1 billion. And same with the operating profit, which was previously 550 million to 750 million. And now it's from €600 million to €750 million.
And here are some upcoming events for this year. And I think at this point, I thank you for your attention and I think it's time for questions.